Dr. Elyse S. Rafal, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 183
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NY license 1915433-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 183
- Services billed
- 1,216
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 512 | 156 |
| Biopsy of related skin growth, first growth | 167 | 87 |
| Destruction of precancer skin growth, 2-14 growths | 113 | 15 |
| Destruction of precancer skin growth, 15 or more growths | 110 | 40 |
| New patient office or other outpatient visit, 30-44 minutes | 75 | 75 |
| Injection into skin growth, 1-7 growths | 74 | 24 |
| Destruction of precancer skin growth, 1 growth | 47 | 23 |
| Application of ultraviolet light to skin | 44 | 13 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Stony Brook, NY | 95 |
| Clindamycin Phosphate Other prescribers in Stony Brook, NY | 34 |
| Mupirocin Other prescribers in Stony Brook, NY | 20 |
| Doxycycline Hyclate Other prescribers in Stony Brook, NY | 18 |
| Ciclopirox Other prescribers in Stony Brook, NY | 15 |
| Calcipotriene | 11 |
| Nystatin Other prescribers in Stony Brook, NY | 11 |
| Oxiconazole Nitrate | 11 |
| Tavaborole | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 77 payments worth $3,117 in total to this clinician.
| Arcutis Biotherapeutics, Inc. | $1,220 |
|---|---|
| Sun Pharmaceutical Industries Inc. | $320 |
| Janssen Scientific Affairs, LLC | $305 |
| AbbVie Inc. | $228 |
| Pfizer Inc. | $176 |
| Journey Medical Corporation | $170 |
| Organon LLC | $116 |
| Janssen Biotech, Inc. | $101 |
| Food and Beverage | $3,034 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $83.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $35.00 |
| AbbVie Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $24.00 |
| AbbVie Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $24.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $176,952 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie Inc. · Active, not recruiting · NCT06118411 - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 60 weeks of treatment with a withdrawal and retreatment period
Takeda Pharmaceuticals U.S.A., Inc. - M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.